THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, August 13, 2026
The pharmaceutical market and custom research services are becoming more important as launch teams face smaller windows to prove value. A drug’s commercial outcome now depends on more than regulatory approval. It depends on payer acceptance, physician adoption, patient access and the ability to respond to competitors quickly.
Many life sciences companies are shifting their attention from protecting margins to finding new sources of growth. McKinsey's 2026 life sciences outlook points to technologies such as agentic AI and robotics, along with expanding consumer channels and new operating models, as some of the forces expected to create that opportunity. As those options grow, companies need research that helps them identify where meaningful growth is genuinely achievable rather than simply promising.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Custom research supports those decisions by answering questions that broad datasets cannot resolve. A company may need to understand why physicians hesitate to prescribe a new therapy, whether payers accept a proposed evidence package or how patients experience current treatment options. Each question requires a research design tailored to the asset and market.
The need is especially strong in complex therapeutic areas. Oncology, immunology, rare disease and metabolic disease markets can change quickly because of trial readouts, guideline updates and new mechanisms of action. A commercial plan built six months before launch may need revision if competitor data changes the market narrative.
The race in obesity medicines has shown how little time companies have to react once a product reaches the market. The Wall Street Journal reported in July 2026 that Novo Nordisk's obesity pill had won nearly 90 percent of new obesity pill prescriptions, leaving Eli Lilly's newly launched pill with a much smaller share. Keeping up with changes like these requires more than periodic market reports. Research teams need a continuous view of physician prescribing, payer coverage and how each brand is being perceived.
Interest in real-world evidence continues to grow as pharmaceutical companies look beyond the results of controlled clinical trials. They also want to understand how physicians, payers and other stakeholders view that evidence in everyday practice. Bringing together claims data, chart reviews, physician interviews and payer insights allows research providers to develop a more complete understanding of how treatments are used and how the market responds.
The challenge is speed. Launch teams often need answers quickly, but rushed research can produce shallow conclusions. Providers that can combine rapid execution with strong methodology will stand out. This is especially important when decisions affect pricing, field force strategy or evidence-generation plans.
The next phase of custom pharma research will likely favor firms that operate as embedded strategy partners. Clients will want continuous market sensing rather than one-off studies that become outdated quickly.
As product launches become more complex, custom research is taking on a much larger role in how pharmaceutical companies prepare for the market. The strongest research partners help teams bring together clinical evidence, market access considerations and stakeholder perspectives early enough to make informed decisions before launch plans are put to the test.
More in News